Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (333)	12/25/1997 6:46:00 PM
From: flickerful	Respond to of 756

with two eyes of coal...? hmm. <eom>

To: 5,17,37,5,101,... who wrote (333)	12/26/1997 6:53:00 AM
From: flickerful	Read Replies (1) \| Respond to of 756

<<offtopic>> i backed into this and i thought it might be interest you...of course, this is not meant to dampen our spirits; just tuck it away. securities.stanford.edu for further listings... securities.stanford.edu randy

To: 5,17,37,5,101,... who wrote (333)	12/26/1997 2:21:00 PM
From: flickerful	Respond to of 756

from the napro thread.... Napro Biotherap(npro), apparently trading was halted around 9am, pending news... Message 3043156 i also saw this: ( i had forgotten this detail...) To: +John McCarthy (197 ) From: +Art Wednesday, Dec 24 1997 7:25PM EST Reply # of 228 John, you asked someone to verify that Anzatax is Faulding's name for Paxene. It is. Here's a quote from the news release detailing the ODAC approval of Paxene along with the source. >>IVAX Corporation markets the product in two South American countries and plans to file applications for marketing in Europe later this year. Through an alliance with F.H. Faulding & Co. Ltd., NaPro's paclitaxel product is sold under the trade name Anzatax(TM) in Australia for refractory breast and ovarian cancers. Faulding also markets the product in China and several countries in the Middle East. Manufacturing facilities in both the U.S. and Canada have been inspected and approved by the Australian Therapeutic Goods Administration, and the U.S. facilities have been inspected but not yet approved by the U.S. FDA.<< Source: Company Press Release: Napro BioTherapeutics, Inc. Announces FDA Advisory Panel Recommendation For Approval of Anti-Cancer Drug Paxene(R)BOULDER, Colo.--(BW HealthWire)--September 19, 1997 Art

To: 5,17,37,5,101,... who wrote (333)	12/26/1997 2:34:00 PM
From: flickerful	Read Replies (1) \| Respond to of 756

<< While NaPro and IVAX are disappointed with FDA's decision, they are pleased that the FDA has determined Paxene(R) to be safe and effective for use in Kaposi's sarcoma and plan to continue to seek marketing authority for Paxene(R) for Kaposi's sarcoma and other indications. >> i see... and now just when do you think we might hear about this again. seven (7) releases in three (3) days plus christmas: did they think we wouldn't notice such lovely post- christmas friday afternoon news? especially after placating us with that flurry of press releases? randy